Investor Relations (IR) Questions: BioTime Inc $BTX
Click here to return to the biotech IRQ Index
Answers received: July 2013
1. When is the last time BTX raised cash through an offering (diluted)?
a. Registered direct placement of $9.0 million in June, 2013
2. How much cash (not cash equivalents) does BTX have?
a. $16 million. Plus our subs have $46 million of tradable BTX stock that they can sell to finance their operations.
3) What and approximately when is the next known catalyst?
a. commencement of clinical trial in EU for Renevia, in 3rd quarter of 2013. Filing of IND in CellCure in early 2014.
4) What is BTX's quarterly cash burn?
a. Approximately $7 million on a consolidated basis
5. Does BTX have an existing line of credit and if so how much can they draw against it?
a. No debt or credit arrangements. We do have approximately $50 million of $5 per share warrants outstanding which are a potential future source of capital
b. We also have an ATM available to sell shares at the market as part of a $75 shelf filing.
1. When is the last time BTX raised cash through an offering (diluted)?
a. Registered direct placement of $9.0 million in June, 2013
2. How much cash (not cash equivalents) does BTX have?
a. $16 million. Plus our subs have $46 million of tradable BTX stock that they can sell to finance their operations.
3) What and approximately when is the next known catalyst?
a. commencement of clinical trial in EU for Renevia, in 3rd quarter of 2013. Filing of IND in CellCure in early 2014.
4) What is BTX's quarterly cash burn?
a. Approximately $7 million on a consolidated basis
5. Does BTX have an existing line of credit and if so how much can they draw against it?
a. No debt or credit arrangements. We do have approximately $50 million of $5 per share warrants outstanding which are a potential future source of capital
b. We also have an ATM available to sell shares at the market as part of a $75 shelf filing.